Experience with independent radiological review during a topotecan trial in ovarian cancer (Q34433444)

2 August 2017

title

Experience with independent radiological review during a topotecan trial in ovarian cancer (English)

1 reference

2 August 2017

1 reference

2

G Bolis

1 reference

2 August 2017

S. Gwyther

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9233526

8 November 2024

M. Gore

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9233526

8 November 2024

W. ten Bokkel Huinink

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9233526

8 November 2024

J. Verweij

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9233526

8 November 2024

I. R. Hudson

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9233526

8 November 2024

R. Despax

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9233526

8 November 2024

A. Jiménez-Lacave

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9233526

8 November 2024

language of work or name

1 reference

1 May 1997

1 reference

2 August 2017

May 1997

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=9233526

full work available at URL

8 November 2024

https://academic.oup.com/annonc/article-pdf/8/5/463/19480823/8-5-463.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A9233526

https://api.elsevier.com/content/article/PII:S0923753419482483?httpAccept=text/xml

8 November 2024

1 reference

https://api.crossref.org/works/10.1023/A:1008241127883

https://api.elsevier.com/content/article/PII:S0923753419482483?httpAccept=text/plain

8 November 2024

1 reference

https://api.crossref.org/works/10.1023/A:1008241127883

http://academic.oup.com/annonc/article-pdf/8/5/463/19480823/8-5-463.pdf

8 November 2024

file format

Portable Document Format

1 reference

https://api.crossref.org/works/10.1023/A:1008241127883

8 November 2024

1 reference

2 August 2017

volume

8

1 reference

2 August 2017

issue

5

1 reference

2 August 2017

page(s)

463-468

1 reference

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

Topoisomerase I inhibitors: topotecan and irenotecan

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

Oral etoposide is active against platinum-resistant epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

Current status of Taxotere (docetaxel) as a new treatment in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada-Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

Advanced breast cancer: a phase II trial with gemcitabine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

Phase II study of gemcitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. EORTC Early Clinical Trials Group and Clinical Screening Group, and the MD Anderson Cancer Center

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

EORTC joint ventures in quality control: Treatment-related variables and data acquisition in chemotherapy trials

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

Chemotherapy administration and data collection in an EORTC collaborative group--can we trust the results?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008241127883

7 January 2021

The addition of etoposide and ifosfamide to cisplatin as second line therapy in ovarian carcinoma

9

1 reference

https://api.crossref.org/works/10.1023/A:1008241127883

8 November 2024

Identifiers

1 reference

2 August 2017

1 reference